See today's BioWorld Asia
To read the full story, subscribe or sign in.

Australia’s Prescient Therapeutics develops next-gen CAR T therapies with UPenn universal immune receptor

June 2, 2020
By Tamra Sami
Prescient Therapeutics Pty Ltd. is poised to develop next-generation CAR T therapies after signing a deal with the University of Pennsylvania for a universal immune receptor technology platform.
BioWorld Asia Deals and M&A License Cancer CAR T Australia